Transcription from a minimal HIV-1 promoter containing the three Sp1 binding sites and TATA box can be activated without Tat by template DNA replication. Here we show that this activation can also be mediated by recombinant GAL4 fusion proteins containing the activation domains of Sp1, VP16 or CTF (or by full-length GAL4) targeted to the HIV-1 promoter by replacing the Sp1 sites with five GAL4 binding sites. Thus Sp1 is not unique in its ability to mediate replication activated transcription, although the degree of processivity elicited by the different activators varied significantly from strongly processive (GAL4-VP16) to relatively non-processive (GAL4-Sp1 or -CTF). Processive GAL4-VP16-activated transcription, but not efficient initiation, required multiple GAL4 binding sites. In the presence of Tat, transcription with GAL4-SP1 and GAL4-CTF was further activated (principally at the level of processivity) but GAL4-VP16-potentiated transcription was only slightly stimulated. The Tat-dependent switch from non-processive to fully processive transcription was particularly marked for GAL4-Sp1, an effect which may be relevant to the selection of Sp1 binding sites by the HIV-1 promoter.
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) relies on both cellular and viral factors for regulated and efficient gene expression. Cis-acting DNA targets for cellular transcription factors and transcriptional activators, including NF-κB, Sp1, TBP and LBP-1, are located in the enhancer and promoter regions of the HIV-1 LTR (reviewed in refs 1 and 2). However, high-level transcription from the HIV-1 promoter is normally dependent on further activation by the viral trans-activator protein, Tat, which increases the efficiency of transcriptional elongation and initiation. These activities are mediated by binding of the Tat protein to a cis-acting element, TAR, located near the 5′ end of each viral primary transcript (reviewed in refs 2 and 3).
When HIV-1 infects a host cell and integrates into its genome, the virus will initially entirely depend on cellular transcription factors, since no Tat will have been synthesised. Clearly, Tat-independent mechanisms of transcriptional activation would be advantageous in this phase of infection, and might subsequently play a role in further activating Tat-mediated transcription. It is now well established that transcriptional activation by DNA replication can potentiate efficient expression from a number of cellular and viral promoters. For example, the human α-globin (4-6), adenovirus major late (7) and adenovirus (minor late) IX promoters (8, 9) all exhibit replication activation in transient assays when expressed from replicating plasmids. Similarly, Patient and co-workers (10, 11) have shown that Xenopus and human β-globin, SV40 early, adenovirus E1A and retroviral LTR promoters are activated by replication in the presence of linked enhancer elements. Replication-mediated transcriptional activation may have important biological functions. It has been suggested that cellular DNA replication, coupled to chromatin restructuring in vivo, may be responsible for programming patterns of eukaryotic gene expression by controlling the accessibility of the DNA to transcription factors (12) . It is also likely that such an activation of viral late promoters is at least partially responsible for the observed transition in gene expression (13) following adenovirus DNA replication; similar early-late transitions have been observed for other DNA viruses (e.g., polyomaviruses-see ref. 14) .
Many of the cells capable of supporting a productive HIV-1 infection have proliferative capacity-indeed, results from a recent study (15) suggest that viral replication in vivo is likely to be restricted to dividing cells (see Discussion). Therefore, activation of transcription from an integrated provirus by cellular DNA replication may have an important influence on viral gene expression. Work in this (6) and other (16) (17) (18) (19) laboratories has addressed the potential relevance of replication activation to HIV-1 gene expression using transiently transfected viral promoter constructs containing SV40 origins of replication. Replication from such origins (reviewed in ref. 20 ) is very similar to cellular DNA replication, occurring in nuclear minichromosomes and using cellular machinery with the addition of a single viral factor, SV40 large T-antigen (Tag). In each study (6, (16) (17) (18) (19) , activation of transcription was observed from HIV-1 promoter plasmids with functional replication origins when Tag was provided in trans. This effect did not require the presence of Tat. Moreover, activation was shown (6) to be dependent on three binding sites for Sp1 adjacent to the TATA box in the viral promoter, but independent of upstream sequences including NF-κB sites and other enhancer elements. This raised the question of whether Sp1 has a unique function in replication activation of this promoter or is simply acting as a general transcriptional activator. To examine further the role of Sp1 in replication activation of a minimal HIV-1 promoter, we have set up a system which is isolated from endogenous cellular Sp1 activity by removal of the Sp1 binding sites. In place of the Sp1 sites, we have inserted binding sites for the yeast trans-activator protein GAL4. This protein has no functional homologues in mammalian cells, but is capable of targeted transcriptional activation in these cells when expressed from a suitable vector (see, for example, 21). Since GAL4 has separable DNA-binding and activation domains (22) , fusion proteins can be expressed from recombinant constructs (23) which bind GAL4 sites but contain functional activation domains from heterologous transcriptional activators. This system has allowed us to test directly whether replication activation mediated by Sp1 relies on the previously characterised transcriptional activation domains of the molecule, and if the activation domains of other activators behave similarly to those of Sp1. The system has also enabled us to investigate co-activation of a replicating HIV-1 promoter by Tat and GAL4 fusion proteins. We have therefore been able to assess whether Tat is specialised to activate transcription in concert with Sp1 (and DNA replication), or whether other activators can substitute for Sp1.
Here we show that transcriptional activation of the HIV-1 promoter by DNA replication can be mediated in trans by an activation domain of Sp1 targeted to a minimal viral promoter by the GAL4 system. The activation domains of CTF, VP16 and GAL4 itself are also functional in this assay, but elicit significantly different patterns of transcription when the number of GAL4 binding sites in the promoter construct is varied. Moreover, Sp1, CTF and VP16 differ in their abilities to co-activate transcription from a replicating template in tandem with Tat, although each supports Tat function. We discuss possible mechanisms for these effects and their potential relevance to HIV-1 gene expression and replication activation in general.
MATERIALS AND METHODS

Plasmid construction
pβE, a construct of P. Lamb that expresses the human β-globin gene, has been described previously (6) . RβSVpBR328, here called pTag, is described in ref. 24 . It expresses both SV40 large T-antigen and rabbit β-globin sequences.
The HIV-1 promoter constructs containing GAL4 binding sites were derived from a variant of HIV/α pSVod (6), which contains the SV40 HindIII-EcoRII 5171-159 fragment (including the origin of replication), and the ScaI-HinfI LTR fragment of HIV-1 (NL4-3) immediately 5′ to human α-globin sequences. The variant used here also had a BglII linker inserted in an NcoI site within the SV40-derived sequence that has previously been shown not to affect plasmid replication. An oligonucleotide (5′-CCTCGAGCCCTCAGATCCTGCATATAAGCAG-3′) was synthesised and inserted into the HIV/α pSVod variant cleaved at unique sites for XmnI (between the SV40 origin and promoter insert) and PvuII (between the Sp1 sites and cap site within the promoter insert). This generated a construct, HIV/α pSVod*, in which the Sp1 sites and other upstream HIV-1 promoter sequences were deleted and an XhoI site was created at the 5′ end of the remaining HIV-1 sequence. Five tandem repeats of the GAL4 binding site CGGAGTACTGTCCTCCG, a variant on the consensus containing an internal ScaI site (21), were excised as an EcoRI-XbaI fragment from pBK103 (a construct of Bernard Khoo which contains the five binding sites cloned into pBlueScript SK+ as a PstI-XbaI fragment). The excised fragment was end-filled and cloned into the end-filled XhoI site of HIV/α pSVod*. This produced a construct, pHαSVo + 5G, containing an intact SV40 origin and five GAL4 binding sites in place of the three Sp1 sites and upstream sequences of the HIV-1 LTR. Partial or full digestion of pHαSVo + 5G with ScaI yielded pHαSVo + 3G (three GAL4 binding sites) and pHαSVo + 1G (one GAL4 site), respectively. Cleavage of each of these three constructs in the SV40 origin region with SfiI, followed by end-filling and ligation with a BglII linker (GAGATCTC) produced pHαSVo -5G, pHαSVo -3G and pHαSVo -1G, equivalent clones lacking functional origins of replication (6, 7, 25) .
pGEMLLTR (constructed by Jan Eggermont) contains the AvaI-HinfI HIV-1 (NL4-3) LTR fragment, end-filled and cloned into pGEM-7Zf(+) at the end-filled XbaI site, in the antisense orientation with respect to the T7 promoter. pGEMSLTR effectively contains the AvaI-SacI LTR fragment of HIV-1 in the antisense orientation relative to the T7 promoter of pGEM-3. It was constructed by excision of a SacI fragment from a variant of HIV-1 LTR HApSP65 (described in ref. 6) , in which the AvaI-HinfI HIV-1 fragment was inserted in the SmaI site of the pSP65 polylinker in the sense orientation with respect to the Sp6 promoter. The SacI fragment was cloned into the SacI site of pGEM-3 and screened for orientation.
pSG4 expresses full-length GAL4 sequences (amino acids 1-881) and employs an SV40 early promoter and polyadenylation signals (as in pSG424, ref. 23 ). The other GAL4 fusion expression vectors were constructed and kindly provided by Bernard Khoo. They are based on pHKG4, a derivative of pSG424 (23) constructed by C. Hagemeier and T. Kouzarides. In this clone the pBR322 plasmid backbone is replaced by ping14 vector sequence (with a BglII-EcoRI deletion). Both pHKG4 and pSG424 express the 1-147 aa domain of GAL4 and carry identical polylinkers, SV40 early promoters/origins and polyadenylation signals. pHKG-CTF, pHKG-VP16 and pHKG-Sp1 (expressing the proline-rich activation domain of CTF, the acidic activation domain of VP16, and the 516C∆int112 serine/threonine-rich and glutamine-rich domains of Sp1-see ref. 26) were derived from equivalent pSG424 constructs (kindly provided by N. Mermod, ref. 27 ) by excising the XbaI-XhoI fragment from each and cloning into similarly cut pHKG4.
pOGS213, which expresses a synthetic tat gene from the human cytomegalovirus immediate early promoter, is described in ref. 28 .
HeLa cell transfection and RNA analysis
The pHαSVo plasmids (10 µg in Fig. 3 , 5 µg in Figs 4, 5 and 6) were transfected with the appropriate GAL4 fusion expression (5). RNAs expressed from the co-transfection control plasmids pβE and pTag were S1 mapped with EcoRI-cleaved, end-labelled probes made from these constructs. RNAs expressed from the pHαSVo constructs were mapped by RNase protection assays (29) using T7 antisense riboprobes expressed from pGEMLLTR (linearised with EcoRI) or pGEMSLTR (linearised with HindIII) labelled with [α-32 P]UTP or [α-32 P]CTP and purified on Stratagene NucTrap columns. Hybridisations were carried out at 56_C for 12-16 h and RNase digestion at 22_C for 30 min. Reproducibility of the patterns of expression observed was confirmed in at least three independent RNase protection assays. Results from a representative assay, with accompanying phosphorimage quantitations (Molecular Dynamics PhosphorImager SF/ImageQuaNT), are presented for each experiment.
In vitro protein-DNA interaction analysis
Whole cell protein extracts were prepared in parallel with cytoplasmic RNA. Half the volume of harvested cell suspension in PBS was pelleted and the pellet washed in 40 mM Tris-HCl pH 7.4; 1 mM EDTA; 150 mM NaCl. The cells were re-pelleted and resuspended in 150 µl of extract buffer (40 mM HEPES pH 7.9, 0.4 M KCl, 1 mM DTT, 10% glycerol; 0.1 mM phenylmethylsulphonyl fluoride, 0.1% Approtinin). The extract was freezethawed three times, the debris was pelleted in a microcentrifuge for 5 min at 14 000 r.p.m., 4_C, and the supernatant was stored at -70_C until required. Protein interactions were assayed by gel mobility shift analysis as previously described (30), using an end-labelled GAL4 binding site DNA fragment.
RESULTS
Experimental design
To investigate replication activation of the HIV-1 promoter, we have employed a modified version of the HIV-1/α-globin gene system described previously (6) . As shown in Figure 1 , the basic construct used, pHαSVo + 5G, contains the SV40 origin of DNA replication (without enhancer) separated from the HIV-1 promoter by 400 bp of vector sequence. The promoter is deleted up to -46 bp from the CAP site which removes the HIV-1 enhancer and three Sp1 binding sites but still retains the TATA box. Five binding sites for the yeast transcription factor GAL4 were then inserted at this deletion end point, adjacent to the TATA box. HIV-1 sequence downstream of the Cap site extends through the TAR region and is then joined to the human α-globin gene from its first intron through to the α-globin poly(A) site. The 5′ ends of transcripts expressed from this construct were detected by RNase protection analysis using two different riboprobes which detect either the first 37 nt of the HIV-1 transcript (SLTR probe) or all of the HIV-1 transcript up to the α-globin gene sequence (LLTR probe). DNA replication of the pHαSVo + 5G plasmid following its transfection into HeLa Cells requires SV40 large T-antigen (Tag) (see ref. 6 ). This was supplied in trans by co-transfection with pTag, a construct that expresses both Tag and rabbit β-globin sequences. Transfection efficiencies were monitored by measuring levels of rabbit β-globin transcripts (as in Figs 4 and 5), or (as in Fig. 3 ) by co-transfection with a third plasmid, pβE, which expresses the human β-globin gene (transcript levels of which were similarly measured).
To allow activation of the HIV-1 promoter through its inserted GAL4 binding sites, plasmids expressing GAL4 binding domain fusion proteins were also co-transfected. These fusion proteins are hybrids of the GAL4 (1-147) DNA binding domain (22) joined to the glutamine-rich activation domain of Sp1, the proline-rich activation domain of CTF, or acidic activation domain of VP16 (plasmids pHKG-Sp1, pHKG-CTF and pHKG- VP16, respectively-see Materials and Methods). The GAL4 DNA binding domain alone, expressed from pHKG4, was used as a negative control. To ensure that these different GAL4 fusion proteins were expressed in HeLa cells and capable of specific DNA binding, nuclear extracts were prepared from HeLa cells transfected with these different plasmids and used in in vitro DNA binding studies. As shown in Figure 2 , using a 32 P-labelled GAL4 binding site oligonucleotide, several non-specific protein complexes form with untransfected HeLa cell nuclear extract (Ctrl., lane 5). However in each case where a plasmid expressing one of the GAL4 fusion proteins was transfected into the HeLa cells, these nuclear extracts gave an extra protein complex band corresponding to the GAL4 fusion protein (lanes 1-4) . The positions of these GAL4 bands are indicated on the figure. To demonstrate the specificity of these GAL4 fusion proteins, the GAL4-CTF extracts were bound to labelled GAL4 DNA in competition with increasing amounts of unlabelled GAL4 competitor DNA (lanes 6-9). As indicated in Figure 2 , the GAL4-CTF band is specifically competed. These in vitro binding experiments therefore demonstrate that expression vectors for each of the GAL4 fusion proteins produce active proteins in HeLa cells which interact with GAL4 binding sites. 
Activation domains stimulate replication-dependent HIV-1 transcription
To determine whether the GAL4 hybrid proteins can stimulate replication-dependent transcription, pHαSVo + 5G was transfected into HeLa cells together with pβE, with or without co-transfected pTag and the various GAL4 fusion expression constructs. RNA was harvested and purified after 48 h and assayed by RNase protection analysis and S1 mapping. The results are shown in Figure 3 . Transfection efficiencies, indicated by the pβE derived human β-globin mRNA S1 bands (Fig. 3c) were similar throughout. From the RNase protection analysis with the SLTR probe (Fig. 3a) it can be seen that in the presence of pTag the GAL4-Sp1, -VP16 and -CTF fusion proteins each stimulate activated transcription from pHαSVo + 5G, although to different degrees. Little or no transcription is observed in the absence of T-antigen, indicating a reliance on replication for significant transcriptional activity. Furthermore, in the absence of co-transfected GAL4 expressing plasmids, virtually no HIV-1 transcripts were detectable. Quantitation of the activation levels seen with the different GAL4-activation domains is shown below Figure 3a . The Sp1 activation effect is given a value of 1 so that it is evident that VP16 gives over a 3-fold greater activation value and CTF a 2-fold lower value than Sp1. These results clearly demonstrate that the replication dependent, activation effect of Sp1 is not unique to this transcription factor as two other factors with different classes of activation domain are also functional in this assay. Even the GAL4 (1-147) DNA binding domain alone gives a low level of activation which is especially evident on a longer exposure of the radioautograph (Fig. 3a, panel ii) . The fact that the GAL4 binding domain retains a small amount of stimulatory activity has been described before in different systems (e.g. 31,32). We reasoned that one possible artefact that would confuse the above results could be that T-antigen may have other transcriptional effects in our system in addition to promoting DNA replication of the pHαSVo + 5G plasmid. We therefore made a second version of this plasmid in which the SV40 origin was inactivated by a linker insertion at the Sfi I site. The experiment described in Figure 3 was then repeated using Tag plasmid in all transfections but alternating the HIV-1 promoter plasmid between forms with and without origin function. As shown in Figure 4a , no detectable HIV-1 transcription was observed when the origins were inactivated or in the absence of GAL4 transcription factors. Furthermore, similar levels of activation relative to Sp1 to those in Figure 3a were obtained for VP16 and CTF domains. An additional experiment was also performed with the whole GAL4 transcription factor (SG4). Levels of activation even higher than those obtained with VP16 were observed, possibly reflecting the fact that SG4 expresses physiological non-chimaeric protein. The GAL4 transcriptional activator contains an acidic activation domain as does VP16. These results 
Activation domains have different effects on transcriptional processivity
An unusual feature of the HIV-1 promoter is that it is capable of synthesising two types of transcript. In the presence of the viral encoded transactivator Tat, HIV-1 transcription is highly processive, reading through the whole viral genome. However, in its absence transcripts are much less processive, resulting in the formation of heterogeneous steady state RNAs extending over only the first 100-200 nt of the coding sequence (see ref. 2 for review). These RNAs are further degraded to a short (∼60 nt) RNA product corresponding to the nuclease resistant TAR hairpin loop at the beginning of the viral transcript. As shown in Figure 3b , we observe this same heterogeneous transcription pattern from our HIV-1/α-globin gene construct using the longer LLTR riboprobe. However we also note that the ratio of transcripts that read through the HIV-1 5′-terminal region to yield full length RNAs (breaking up into three major bands due to variable digestion with the RNases used in the RNase protection experiment) as compared to shorter RNAs that accumulate at ∼60 nt (over the TAR region) significantly changes with the different activation domains. Quantitation of the ratio of full to short length RNAs reveals that Sp1 stimulates non-processive transcription while VP16 produces mainly full length transcripts. These results are consistent with recent studies (33, 34) which show that different transcription factors may have differential effects on transcriptional initiation and elongation. We also show that both the CTF activation domain and the residual activation properties of the GAL4 binding domain alone stimulate non-processive transcription. In Figure 4b we confirm these results although the degree of ratio change between the Sp1, CTF and VP16 activation domains is slightly reduced. The strongly activating full length GAL4 transcription factor (SG4) gives an intermediate ratio of processive to non-processive HIV-1 transcription.
Different activation domains have dissimilar effects when targeted to the HIV-1 promoter by a single GAL4 binding site
As described above, previous work in this laboratory has demonstrated that three upstream Sp1 sites potentiate replication activation of the HIV-1 promoter (6). Here it was also shown that two Sp1 sites, or even a single site, were sufficient to stimulate HIV-1 transcription to some degree. Levels of stimulation, however, were significantly higher when three binding sites were employed. To determine whether the HIV-1/α-globin gene construct used here behaves similarly, we constructed variants of pHαSVo + 5G and pHαSVo -5G that contained three GAL4 binding sites (pHαSVo + 3G and pHαSVo -3G) or a single site (pHαSVo + 1G and pHαSVo -1G). Transfections and RNA analyses were carried out as described above. Results obtained using pHαSVo + 3G and pHαSVo -3G were similar to those from the experiments with pHαSVo + 5G and pHαSVo -5G (data not shown). However, the results obtained with pHαSVo + 1G and pHαSVo -1G were markedly different. Figure 5 shows data from a 1-GAL4 binding site experiment conducted in parallel with the 5-GAL4 binding site experiment shown in Figure 4 . Use of the single GAL4 site in place of the five sites led to a general reduction in the degree of replication activation, with some notable differential effects between activators. Most strikingly, the level of replication activation mediated by full-length GAL4 was reduced to lower levels than with GAL4-Sp1; similarly GAL4-CTF activation was reduced to very low levels. Significantly, although GAL4-VP16 was still capable of mediating replication activation to high levels, the ratio of full-length to short transcripts detected by the LLTR probe was markedly lower than observed before, suggesting that multiple GAL4 binding sites are required for effects on transcriptional elongation but are less important for initiation (see Discussion).
Activation domains differ in their abilities to activate a replicating HIV-1 promoter in tandem with Tat
Although DNA replication may have an important role in activating early viral transcription before significant amounts of Tat are synthesised, it is equally possible that such activation continues to function at a later stage in combination with trans-activation by Tat. We therefore wished to investigate how the two activation mechanisms interact. In particular we were interested in determining whether Sp1 is uniquely suitable for co-operation with Tat, since previous studies in non-replicating systems (35) (36) (37) (38) (39) have reached different conclusions on its necessity.
As shown in Figure 6 , the minimal HIV-1 promoter construct requires a functional origin of replication for significant expression even in the presence of Tat and each of the three activators tested. Transcription was detectable (using a longer radioautograph exposure than shown) from a non-replicating template when activated by Tat plus GAL4-Sp1, -VP16 or -CTF, but levels were >10-fold lower than those obtained with a replicating promoter, reflecting the large effect that replication activation has in this system. It should be noted, however, that intermediate levels of transcription (see ref. 6) can be obtained from a non-replicating promoter carrying wild-type Sp1 sites which allow more efficient activation by endogenous non-chimaeric Sp1.
When the levels of transcription from a replicating template with and without Tat are compared, there are clear differences between the activators, although each supports Tat function. Transcription activated by Sp1, or to a lesser extent by CTF, becomes markedly more processive in the presence of Tat (8.7-or 2.7-fold increase, respectively). However, transcription activated by VP16, in which elongation is already highly efficient, becomes only marginally (1.2-fold) more processive in the presence of Tat. Similarly, total levels of transcription, and hence levels of initiation, are significantly increased by Tat when Sp1 or CTF is the activator (4-6-fold total increase), whereas in the case of VP16 this increase is slight. In general, the pattern of transcription activated by Sp1 or CTF in the presence of Tat is similar to that obtained with VP16 with or without Tat.
DISCUSSION
In this paper we have shown that the chimaeric transcription factors GAL4-Sp1, GAL4-VP16 and GAL4-CTF as well as intact GAL4, when targeted to GAL4 binding sites upstream of the minimal HIV-1 promoter, potentiate transcriptional activation by DNA replication in transient assays. The precise patterns of transcription obtained with each of the four activators varied significantly, especially when the number of GAL4 binding sites was reduced from five to one. GAL4-Sp1, GAL4-VP16 and GAL4-CTF were also tested for their ability to co-operate with Tat in trans-activating a replicating promoter; each was able to support Tat function to some extent, but only transcription activated by GAL4-Sp1 and GAL4-CTF underwent significant further activation when Tat was added. In particular, Tat induced a dramatic shift from non-processive to processive transcription from a promoter activated by GAL4-Sp1.
The ability of the GAL4-Sp1 construct to mediate replication activation is consistent with and extends the finding (6) that native and foreign Sp1 sites confer responsiveness to replication activation on HIV-1 and β-globin promoters. The present results strongly suggest that the previously observed requirement for Sp1 sites is a consequence of the need to recruit endogenous Sp1 to the promoter to elicit a functional response, rather than a direct cis-acting effect of the GC-rich binding sites. It is also clear from our assays with GAL4-VP16, GAL4-CTF and GAL4 that Sp1 has no unique activity required for potentiating replication activation. Indeed, the simplest interpretation of our results is that conventional mechanisms of transcriptional activation, mediated by well-defined activation domains, are operating in tandem with DNA replication to induce relatively high levels of expression from the HIV-1 promoter in the absence of Tat. Although this does not invalidate the previous suggestion (6) that the (Sp1) n -TATA region is important for activating transcription from replicating templates, it is clear that promoters containing binding sites for other transcriptional activators may also be responsive to replication activation. Patient and co-workers, whose initial work demonstrated a replication activation effect on β-globin gene transcription that required the SV40 enhancer (10) , have more recently shown that a similar effect can be obtained using multimerised binding sites for specific factors (e.g., octamer motifs) in place of the enhancer (11) . Taken together with these results, our data may reflect a general mechanism by which DNA replication can activate transcription in concert with a variety of trans-acting factors which bind either at distal (enhancer) or proximal (promoter) sites. Interestingly, transcriptional activators including GAL4 and GAL4-VP16 have been shown to be functional when bound at remote locations (40) .
The pattern of GAL4-VP16 activated transcription from the replicating HIV-1 promoter construct containing five GAL4 sites is consistently different from that obtained with the other activators. The ratio of full-length to short, truncated transcripts is markedly higher with GAL4-VP16, suggesting that GAL4-VP16 action involves effects on both transcriptional initiation and elongation. Indeed, Yankulov et al. (33) have found that GAL4-VP16, when targeted to various promoters by multiple GAL4 binding sites, stimulates elongation as well as initiation in Xenopus nuclei and 293 cells. Comparable results for the c-myc promoter have recently been published by Krumm et al. (34) . Surprisingly, we observed a different pattern of expression when GAL4-VP16 was used to activate the promoter construct containing only one GAL4 binding site. Although high levels of transcriptional activation were again observed, the ratio of full-length to short transcripts dropped markedly. This suggests that interaction with one site is sufficient to stimulate initiation but not elongation. It is possible that some form of synergistic interaction between activators that enhances elongation occurs when multiple binding sites are available (perhaps by allowing multiple contacts with both initiation and elongation factors). The synergistic activity of GAL4-VP16 when targeted to multiple binding sites has been reported previously (32, (41) (42) (43) , although in this case it was reduced by replication (43) . Similarly, it has been shown (32) that a GAL4 derivative bearing a single GAL4 activation domain activates transcription >300-fold more efficiently when targeted to five binding sites as it does when targeted to one. The CAT and luciferase reporter gene assays used in these experiments did not distinguish between activator effects on initiation and elongation. It is therefore possible that differences in processivity underlie the observed synergistic effects.
The mechanism by which DNA replication stimulates transcriptional activation is unclear. Previous work in this laboratory (6) has established that SV40 origin-containing plasmids do not replicate efficiently in HeLa cells under identical experimental conditions to those used here, ruling out a simple copy number effect (others have reached similar conclusions using HeLa and COS cells-see refs [7] [8] [9] [10] [11] 18) . Nevertheless, low level replication appears to produce a transcriptional template that is more responsive to activators. For reasons discussed previously (6) we do not consider a mechanism based on differences in DNA methylation to be likely, although it remains possible that the subnuclear position or conformation of newly-replicated plasmid DNA favours its transcription if activators are available. The unwinding of the DNA duplex which occurs in response to Tag binding (25) may also be a factor. However, an alternative explanation is possible. Plasmids containing SV40 origins, when transfected into mammalian cells, are known to be assembled into chromatin structures which are restructured when the DNA is replicated (44) . Nucleosomes compete with transcription factors for access to DNA (reviewed in ref. 45 ) but DNA replication causes a transient disruption in chromatin structure followed by a staged reassembly process. This may allow ready access of transcription factors to their binding sites (even after core histones have bound); nucleosome maturation progressively blocks such interactions (12) . Furthermore, Kamakaka et al. (46) have found in vitro evidence for a replication-dependent chromatin reconfiguration mechanism for transcriptional activation by GAL4-VP16. Such an explanation is plausible for the episomal replication activation described here, and may also be applicable to activation of integrated viral DNA.
The final experiments described in this study indicate that replication activation mediated by each of the three activators tested can co-operate with the viral trans-activator, Tat. Differences in the patterns of co-activation observed may have relevance to the question of why Sp1 was 'selected' as a transcriptional activator by HIV-1. Previous analyses in non-replicating systems have reached varying conclusions on whether Sp1 is an essential co-activator for Tat. Jeang and co-workers (35, 36) have found that activators such as Oct-1 and NF-κB are poor substitutes for Sp1 in co-operating with Tat function. Co-activation ability was found to correlate with the strength of physical interaction between the activator and Tat. One recent study, using a heterologous chimaeric promoter (37) has defined further activators that co-operate poorly with Tat (Bel-1, E1a and Tax) but has also concluded that others, including VP16 and CTF, synergise with Tat at least as well as Sp1. In contrast, two other groups (38, 39) have found that synergy is much greater between Sp1 and Tat than it is between VP16 and Tat; adding Tat did not increase levels of expression much beyond those obtained with VP16 alone. The latter results are consistent with those obtained in our replicating system. Moreover, unlike the previous studies which relied on chloramphenicol acetyl transferase reporter gene assays (35) (36) (37) (38) (39) we have made direct comparisons between the abilities of Sp1, VP16 and CTF to co-operate with Tat by RNA analysis. From this analysis, we can conclude that a major reason for the inability of VP16 to synergise with Tat to the same extent as Sp1 is its different mechanism of action (although we also note that VP16-activated transcription appears to be less sensitive to stimulation of transcriptional initiation by Tat than Sp1 or CTF-activated transcription). In our system, transcription activated by VP16 even in the absence of Tat is already highly processive. Since a major function of Tat is to increase elongation efficiency, further activation by Tat has only a limited effect. In contrast, RNA transcribed in the presence of Sp1 (especially) or CTF elongates relatively inefficiently, so additional effects of Tat are more significant. Indeed, the Sp1+Tat and CTF+Tat phenotypes are similar to that obtained with VP16 (irrespective of Tat). We suggest that the selection of a 'two-stage' activation mechanism involving a cellular activator (Sp1) that operates primarily on transcriptional initiation and synergises with a viral regulator of transcript elongation (Tat) may have regulatory advantages for the virus. A two-component regulatory system may allow more flexible control of gene expression than activation by a factor such as VP16 that strongly affects both initiation and elongation. Sp1-mediated replication activation may initially induce an 'early' pattern of transcription balanced between full-length and short transcripts which progresses to a 'late' processive pattern when adequate amounts of Tat are synthesised. Alternatively, the virus may simply have evolved Tat as a regulatory protein that complements an existing cellular activator, rather than duplicating all its functions.
To what extent DNA replication influences HIV-1 transcription in vivo is as yet unknown. From the present results it is only possible to say that the viral promoter is certainly responsive to replication activation, and that this process could potentially activate HIV-1 gene expression in infections of proliferating cells. Since HIV-1 is capable of productively infecting macrophages (usually regarded as non-dividing) and growth-arrested cells (47) , replication activation may only be relevant to a subgroup of cellular infections. However, in a recent study (15) it was concluded that productive infection of macrophages requires cellular factors only present in a small proportion of these cells with proliferative capacity, suggesting that HIV-1 infection in vivo is restricted to dividing cells. Thus replication activation could have a more general role in stimulating viral gene expression. In either case, studies of integrated viral constructs or provirus should provide a clearer picture of the relevance of this type of activation to HIV-1, while analyses of chromatin structure may provide more insight into its molecular mechanism.
